林业发展局批准Papzimeos,第一次治疗RPP,这是一种罕见的与HPV有关的呼吸系统疾病。 FDA approves Papzimeos, first treatment for RRP, a rare HPV-related respiratory condition.

美国食品和药物管理局批准了Papzimeos,这是有史以来首次用于复发性呼吸道乳头瘤病 (RRP) 的成年患者的治疗,这是HPV引起的罕见疾病. The FDA has approved Papzimeos, the first-ever treatment for adult patients with recurrent respiratory papillomatosis (RRP), a rare disease caused by HPV. Papzimeos在12周内通过四次注射分娩,刺激免疫系统与六和十一型HPV进行抗争,从而减少了对频繁手术的需要。 Delivered through four injections over 12 weeks, Papzimeos stimulates the immune system to fight HPV types 6 and 11, reducing the need for frequent surgeries. 这一批准是根据显示安全和有效性的临床试验数据作出的,导致Precigen的库存大幅增加。 The approval, based on clinical trial data showing safety and effectiveness, led to a significant surge in Precigen's stock. 影响美国约27 000名成人的RRP涉及气道中的良性肿瘤,这些肿瘤可能威胁生命。 RRP, affecting around 27,000 adults in the US, involves benign tumors in the airways that can be life-threatening.